News | November 07, 2024
Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company uses iPS cells to develop treatments for diseases relating to the kidney
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Subscribe To Our Newsletter & Stay Updated
